EPCAM_HUMAN M4S1 ELISA tesk kit
- Known as:
- EPCAM_HUMAN M4S1 Enzyme-linked immunosorbent assay test tesk reagent
- Catalog number:
- gen16481
- Product Quantity:
- 1
- Category:
- Peptides
- Supplier:
- Other suppliers
- Gene target:
- EPCAM_HUMAN M4S1 ELISA tesk kit
Related genes to: EPCAM_HUMAN M4S1 ELISA tesk kit
- Gene:
- EPCAM NIH gene
- Name:
- epithelial cell adhesion molecule
- Previous symbol:
- M4S1, MIC18, TACSTD1
- Synonyms:
- Ly74, TROP1, GA733-2, EGP34, EGP40, EGP-2, KSA, CD326, Ep-CAM, HEA125, KS1/4, MK-1, MH99, MOC31, 323/A3, 17-1A, TACST-1, CO-17A, ESA
- Chromosome:
- 2p21
- Locus Type:
- gene with protein product
- Date approved:
- 1995-10-02
- Date modifiied:
- 2019-04-23
Related products to: EPCAM_HUMAN M4S1 ELISA tesk kit
Related articles to: EPCAM_HUMAN M4S1 ELISA tesk kit
- Tumor-derived exosomes carry multi-scale molecular signatures (e.g., surface proteins and nucleic acids) that reflect tumor heterogeneity, yet simultaneously profiling these biomarkers in single intact vesicles remains technically challenging. Herein, we developed a digital droplet microfluidic platform that integrates a DNA walker and a CRISPR/Cas13a system for the simultaneous detection of surface proteins (EpCAM, HER2) and miRNA (miR-21) at the single exosome level. This platform employed engineered liposome nanoprobes (eLipo-NPs) with EpCAM aptamers and hairpin probes (HPs) functionalized on their outer membranes, and encapsulated a CRISPR/Cas13a system within their lumen. Upon co-encapsulation with single exosomes into droplets, EpCAM-mediated membrane fusion redistributed HPs across the hybrid membrane and delivered CRISPR/Cas13a into the exosomes. The membrane-anchored DNA walker then bound HER2 and drove cyclic DNAzyme cleavage of HPs to restore red fluorescence. At the same time, crRNA-guided Cas13a recognized miR-21 and triggered trans-cleavage of reporters to generate green fluorescence. Digital counting of dual-positive droplets enabled quantitative single-exosome analysis with a limit of detection (LOD) of 10 particles/μL and a detection time of 60 min. Clinical validation using plasma-derived exosomes from 24 breast cancer patients and 14 healthy donors demonstrated distinct distributions among HER2-positive, HER2-negative, and healthy control groups, with the percentage of dual-positive droplets significantly correlated with clinical HER2 status, highlighting the platform's potential for liquid biopsy and precision oncology. - Source: PubMed
Publication date: 2026/05/25
Xiao ShuSong JialeiChen HaitianYin WenYan XijingHu KunpengShi JingyuYang Mo - The clinical implementation of circulating tumor cells (CTCs) as a predictive tool for therapy efficacy in the growing field of precision oncology likely requires advanced CTC phenotyping. While their predictive value for disease progression and therapy response has extensively been shown, the low number of CTCs that are obtained from whole blood tubes limits their clinical application. The magnetic enrichment of CTCs using the FDA-cleared CellSearch system is limited by the expression of the epithelial cell adhesion molecule (EpCAM) on CTC, and an increase in CTC yield may be obtained through enhanced capture of low EpCAM expressing cells. In this study, we compared the Flow Enabled Target Capture Halbach (FETCH) magnetic enrichment technology with the FDA-cleared CellSearch system for CTC capture using paired blood samples from 34 patients with non-small-cell lung, breast, and prostate cancer. Results show a statistically significant median 1.5-fold increase in CTCs captured with the FETCH system compared with CellSearch, accompanied by a median twofold reduction in non-specifically captured leukocytes. This increase in CTC capture can aid the comprehensive analysis of CTCs in a larger number of patients, further supporting clinical implementation of CTC-based diagnostics. - Source: PubMed
Publication date: 2026/05/29
Stevens MichielMentink AnoukNiessink TomCoumans FrankMekenkamp LeonieBansal RuchiHiltermann Jeroen - Translational medicine remains one of the central challenges in modern biomedical research. A major bottleneck in this field is the limited availability of suitable animal models that reliably predict human disease outcomes. Large animal models, particularly pigs, are increasingly recognized as promising preclinical systems for translating fundamental immunological and oncological discoveries into clinically relevant applications. - Source: PubMed
Publication date: 2026/05/13
Lee JinsilCañas Crespo ClaraHammacher TimLazar AndreiGuenther Eva MJohne MarieWeiß WiebkeDau Tung HuyMaksimov PavloFlisikowski KrzysztofLyndin MykolaZimmermann WolfgangSchleer HubertusKammerer Robert - Silk sericin, a hydrophilic protein extracted from Bombyx mori cocoons, has emerged as a promising biomaterial for wound healing applications due to its bioactivity and cost-effective production. In this study, isolated sericin was characterized by Fourier transform infrared (FTIR) spectroscopy and mass spectrometry, confirming high purity with minimal fibroin contamination. Endotoxin contamination was excluded by LAL gel clot assay (<0.03 EU/mL). In vitro studies using human keratinocytes (HaCaT) and rat fibroblasts demonstrated that sericin at 600 μg/ml significantly enhanced cell viability (30% increase, p < 0.01) and accelerated in vitro wound healing (p < 0.001). Real-time PCR and Western blot analyses revealed modulation of cytokeratins 16 and 17 (KRT16/17) and up-regulation of junctional adhesion molecule A (JAM-A), suggesting enhanced epithelial activation and cell-cell adhesion. This response coincided with increased NF-κB and IL-17 expression. In fibroblasts, sericin significantly increased the expression of matrix metalloproteinase-9 (MMP9) and vascular endothelial growth factor (VEGF) (p < 0.01), suggesting pro-remodeling and pro-angiogenic potential. In HaCaT cells, sericin induced a transient increase in IL-1β (p < 0.01) followed by a reduction in tumor necrosis factor α (TNF-α) (p < 0.05) and an increase in IL-10 at 48 h. In THP-1-derived macrophages, sericin reduced IL-1β and TNF-α (p < 0.001), increased IL-10 (p < 0.05), and shifted polarization toward the M2 phenotype, as indicated by upregulation of CD163 and downregulation of CD86 (p < 0.001). Sericin showed no antibacterial activity against Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus aureus. Its accessibility, cytocompatibility, and ability to modulate epithelial activation, matrix-remodeling responses, and inflammation position sericin as a promising candidate for advanced wound care strategies. - Source: PubMed
Publication date: 2026/05/27
Mazurek ŁukaszLaskowska AnnaRybka MateuszZajdel MikołajSzudzik MateuszSalagierski SzymonDziadek MichałSitkiewicz EwaStradczuk-Mazurek MonikaFrankowski JakubSchwartz RobertKonop Marek - Large extracellular vesicles (large EV) released from tumor and benign cells are detectable in blood and hold potential as non-invasive biomarkers. While their diagnostic relevance has been shown in several malignancies, their role in head and neck squamous cell carcinoma (HNSCC) remains insufficiently characterized. - Source: PubMed
Publication date: 2026/05/27
Büntzel JudithMaulhardt MarkusAngleitner Alexander CasimirSchulz MatthiasKöberle DanielNaser SaidZwerenz ClaraPagel Charlotta FriederikeHille AndreaHund Anna-CarinaBüntzel Jens